Guardant Health (GH) is trading lower as the market reacts to FDA briefing documents released ahead of AstraZeneca’s camizestrant advisory committee meeting, highlighting concerns with the SERENA-6 strategy—an approach that uses circulating tumor DNA to detect ESR1 mutations and trigger an early therapy switch. Because Guardant’s Guardant360 test is embedded in the SERENA-6 design, investors are treating the FDA’s skepticism as a read-through risk to the timing and magnitude of any incremental testing volumes that a camizestrant approval could unlock for Guardant.

The FDA’s briefing materials emphasize the central question of whether switching therapy based on a molecular signal—before radiographic progression—may limit patients’ benefit from existing therapy, raising uncertainty around the approvability and label breadth for camizestrant in this setting. For Guardant, the issue is less about current product performance and more about whether the intended clinical workflow expands quickly post-approval, which would influence how fast Guardant360 volumes could ramp in ESR1 monitoring tied to this paradigm shift.

Separately, Guardant disclosed on April 27, 2026 that Chief Medical Officer Craig Eagle, M.D. will resign effective May 8, 2026. While a single executive departure doesn’t change the company’s underlying portfolio on its own, the timing—arriving into a high-visibility regulatory moment tied to a key partner program—can amplify investor caution and contribute to risk-off positioning in the stock.